ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

2 Indian drugmakers seek approval for COVID-19 vaccines

Move follows Pfizer application, with first licensing possible in a few weeks

Passengers wait in line to have their temperature checked at a railway station in Mumbai on Nov. 26.   © Reuters

NEW DELHI -- Two Indian companies have applied for emergency approval of their COVID-19 vaccine candidates in a country that is the second-worst hit by the coronavirus pandemic, days after U.S. drugmaker Pfizer did the same.

The Pune-based Serum Institute of India, or SII -- a manufacturing partner for the Covishield vaccine candidate from Oxford University and AstraZeneca -- and Hyderabad-based Bharat Biotech, which is developing an indigenous vaccine called Covaxin, have sought emergency use authorization, Health Secretary Rajesh Bhushan told a media briefing on Tuesday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more